ArticleBulletin of experimental biology and medicine2025
Dynamics of Endogenous Somatostatin and the Infarct-Limiting Effect of Octreotide in a Rat Model of Long-Term Ischemia/Reperfusion.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outbred male Wistar rats underwent coronary artery occlusion (45 min) followed by reperfusion (120 min), and the infarct size to area at risk (IS/AAR) ratio was determined. For 8 days prior to coronary occlusion, rats were subcutaneously administered octreotide at doses of 20 and 40 μg/kg. In the control group rats, the levels of endogenous somatostatin were measured before occlusion and at the 120th minute of reperfusion. Preventive administration of 40 μg/kg octreotide reduced the levels of creatine kinase-MB (CK-MB) and infarct size by decreasing the necrosis area. Octreotide at a dose of 20 μg/kg produced no infarct-limiting effect. Control animals exhibited increased endogenous somatostatin levels by the end of reperfusion (in comparison with baseline), which negatively correlated with CK-MB levels.
Indexed as
Identifiers
41806347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.